Process development of TRI-999, a fatty-acid-modified HIV fusion inhibitory peptide

Organic Process Research and Development

Volumn 12, Issue 1, 2008, Pages 101-110

  Zhang, Huyi ^a   Schneider, Stephen E ^a   Bray, Brian L ^a   Friedrich, Paul E ^a   Tvermoes, Nicolai A ^a   Mader, Catherine J ^a   Whight, Sheila R ^a   Niemi, Toivo E ^a   Silinski, Peter ^a   Picking, Tony ^a   Warren, Marquitta ^a   Wring, Stephen A ^a  

^a Trimeris Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38949106122     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op7002198     Document Type: Article

References (26)

1. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: the first therapy to inhibit the entry of HIV-I into host CD4 lymphocytes. Nat. Rev. Drug Discovery 2004, 3 (3), 215-225.
2. Smith, S. M. New York City HIV superbug: fear or fear not. Retrovirology 2005, 2, 14-16.
3. Greenberg, M. L.; Cammack, N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 2004, 54 (2), 333-340.
4. Gibbs, N. A.; Baylor, M. S.; Johann-Liang, R. Injection site reactions, injection difficulties, and interventions in enfurvitide pivotal clinical trials: Focus on subject tolerability. In 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005.
5. Chicharro, C.; Granata, C.; Lozano, R.; Andreu, D.; Rivas, L. N-Terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hydrid peptide. Antimicrob. Agents Chemother. 2001, 45 (9), 2441-2449.
6. Chu-Kung, A. F.; Bozzelli, K. N.; Lockwood, N. A.; Haseman, J. R.; Mayo, K. H.; Tirrell, M. V. Promotion of peptide antimicrobial activity by fatty acid conjugation. Bioconjugate Chem. 2004, 15 (3), 530-535.
7. Dasgupta, P.; Singh, A.; Mukherjee, R. N-Terminal acylation of somatostatin analog with long chain fatty acids enhances its stablity and anti-proliferative activity in human breast adenocarcinoma cells, Biol: Pharm. Bull. 2002, 25 (1), 29-36.
8. Ekrami, H. M.; Kennedy, A. R.; Shen, W.-C. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett. 1995, 371 (3), 283-286.
9. Knudsen, L.; Nielsen, P.; Huusfeldt, P.; Johansen, N.; Madsen, K.; Pedersen, F. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000, 43, 1664-1669.
10. Shen, W. C.; Honeycutt, L. R.; Ekrami, H.; Wang, J. In Pharmacokinetics and biodistribution of PAL-BBI, a fatty acid-polypeptide conjugate, Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 1996; Controlled Release Society, Inc.: St. Paul, MN, 1996; pp 887-888.
11. Verheul, A. F. M.; Udhayakumar, V.; Jue, D. L.; Wohlhueter, R. M.; Lal, A. A. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids. J. Immunol. Methods 1995, 182, 219-226.
12. Wang, J.; Wu, D.; Shen, W.-C. Structure-activity relationship of reversibly lipidized peptides: Studies of fatty acid-desmopressin conjugates. Pharm. Res. 2002, 19 (5), 609-614.
13. Wang, Q.; Graham, K.; Schauer, T.; Fietz, T.; Mohammed, A.; Liu, X.; Hoffend, J.; Haberkorn, U.; Eisenhut, M.; Mier, W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl. Med. Biol. 2004, 31 (1), 21-30.
14. Yahalom, D.; Koch, Y.; Ben-Aroya, N.; Fridkin, M. Synthesis and bioactivity of fatty acid-conjugated GNRH derivatives. Life Sci. 1999, 64 (17), 1543-1552.
15. Delmedico, M. K.; Bray, B. L.; Cammack, N.; Davison, D. K.; Dwyer, J. J.; Frick, L. W.; Tvermoes, N. A.; Wring, S. A.; Zhang, H.; Greenberg, M. L. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. In 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006.
16. Wring, S. A.; Frick, L. W.; Greenberg, M. L.; Jin, L.; Ohmstede, C.; Parham, R. M.; Razook, C.; Schneider, S. E.; Tvermoes, N. A.; ZHANG, H.; Cammack, N.; Delmedico, M. TRI-999, a next generation fusion inhibitor: Fatty acid-based conjugates enhance the potency and pharmacokinetic properties of a gp41 HR2 domain peptide. In 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC™), San Francisco, CA, 2006.
17. Wring, S. A.; Bray, B. L.; Davson, D. K.; Delmedico, M. K.; Greenberg, M. L.; Jin, L.; Matthews, T.; Niemi, T. E.; Ohmstede, C. A.; Parham, R. M.; Razook, C.; Schneider, S. E.; Tvermoes, N. A.; Whight, S. R.; Zhang, H.; Frick, L. W. Structure activity relationships of fatty acid-PEG based conjugates to enhance the potency, pharmacokinetic properties and genetic barrier to resistance of an HIV-1 gp41 HR2 domain fusion inhibitor peptide. Unpublished work.
18. Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discovery 2003, 2 (7), 587-593.
19. Schneider, S. E.; Bray, B. L.; Mader, C. J.; Friedrich, P. E.; Anderson, M. W.; Taylor, T. S.; Boshernitzan, N.; Niemi, T. E.; Fulcher, B. C.; Whight, S. R.; White, J. M.; Greene, R. J.; Stoltenberg, L. E.; Lichty, M. Development of HIV fusion inhibitors. J. Peptide Sci. 2005, 11 (11), 744-753.
20. Wring, S.; Frick, L.; Schneider, S.; Zhang, H.; Di, J.; Heilman, D. Fatty acid conjugates with HIV gp41-derived peptide for treatment of HIV infections. WO 2006105201, 20061005, 2006.
21. Schneider, S.; Mader, C. J.; Bray, B.; Tvermoes, N.; Zhang, H. Methods and Compositions for Synthesis of Peptides and Related Conjugates. WO 2006105199 20061005, 2006.
22. Kisfaludy, L.; Schon, I. Preparation and applications of pentafluorophenyl esters of 9-fluorenylmethyloxycarbonyl amino acids for peptide synthesis. Synthesis 1983, (4), 325-327.
23. Kang, M.-c.; Bray, B.; Lichty, M.; Mader, C.; Merutka, G. Methods and composition for peptide synthesis (T-20). US 6015881, 20000118, 2000.
24. Carpino, L. A.; Han, G. Y. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J. Am. Chem. Soc. 1970, 92 (19), 5748-5749.
25. Vojkovsky, T. Detection of secondary amine on solid phase. Peptide Res. 1995, 8 (4), 236-237.
26. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34 (2), 595-598.